Copyright © 2008 Lucie Khemtémourian et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

1. P. Westermark, “Fine structure of islets of Langerhans in insular amyloidosis,” Virchows Archiv A, vol. 359, no. 1, pp. 1–18, 1973. View at Publisher · View at Google Scholar
2. P. Westermark, C. Wernstedt, E. Wilander, D. W. Hayden, T. D. O'Brien, and K. H. Johnson, “Amyloid fibrils in human insulinoma and islets of Langerhans of the diabetic cat are derived from a neuropeptide-like protein also present in normal islet cells,” Proceedings of the National Academy of Sciences of the United States of America, vol. 84, no. 11, pp. 3881–3885, 1987. View at Publisher · View at Google Scholar
3. G. J. S. Cooper, A. C. Willis, A. Clark, R. C. Turner, R. B. Sim, and K. B. M. Reid, “Purification and characterization of a peptide from amyloid-rich pancreases of type 2 diabetic patients,” Proceedings of the National Academy of Sciences of the United States of America, vol. 84, no. 23, pp. 8628–8632, 1987. View at Publisher · View at Google Scholar
4. A. Clark, C. E. Lewis, A. C. Willis, et al., “Islet amyloid formed from diabetes-associated peptide may be pathogenic in type-2 diabetes,” The Lancet, vol. 330, no. 8553, pp. 231–234, 1987. View at Publisher · View at Google Scholar
5. A. Lorenzo, B. Razzaboni, G. C. Weir, and B. A. Yankner, “Pancreatic islet cell toxicity of amylin associated with type-2 diabetes mellitus,” Nature, vol. 368, no. 6473, pp. 756–760, 1994. View at Publisher · View at Google Scholar · View at PubMed
6. T. D. O'Brien, P. C. Butler, D. K. Kreutter, L. A. Kane, and N. L. Eberhardt, “Human islet amyloid polypeptide expression in COS-1 cells. A model of intracellular amyloidogenesis,” American Journal of Pathology, vol. 147, no. 3, pp. 609–616, 1995.
7. J. Janson, R. H. Ashley, D. Harrison, S. McIntyre, and P. C. Butler, “The mechanism of islet amyloid polypeptide toxicity is membrane disruption by intermediate-sized toxic amyloid particles,” Diabetes, vol. 48, no. 3, pp. 491–498, 1999. View at Publisher · View at Google Scholar
8. H. J. Hiddinga and N. L. Eberhardt, “Intracellular amyloidogenesis by human islet amyloid polypeptide induces apoptosis in COS-1 cells,” American Journal of Pathology, vol. 154, no. 4, pp. 1077–1088, 1999.
9. E. L. Saafi, B. Konarkowska, S. Zhang, J. Kistler, and G. J. S. Cooper, “Ultrastructural evidence that apoptosis is the mechanism by which human amylin evokes death in RINm5F pancreatic islet $\beta$-cells,” Cell Biology International, vol. 25, no. 4, pp. 339–350, 2001. View at Publisher · View at Google Scholar · View at PubMed
10. C. Betsholtz, L. Christmansson, U. Engström, et al., “Sequence divergence in a specific region of islet amyloid polypeptide (IAPP) explains differences in islet amyloid formation between species,” FEBS Letters, vol. 251, no. 1-2, pp. 261–264, 1989. View at Publisher · View at Google Scholar
11. J. W. M. Höppener, C. Oosterwijk, M. G. Nieuwenhuis, et al., “Extensive islet amyloid formation is induced by development of type II diabetes mellitus and contributes to its progression: pathogenesis of diabetes in a mouse model,” Diabetologia, vol. 42, no. 4, pp. 427–434, 1999. View at Publisher · View at Google Scholar
12. P. Westermark, U. Engström, K. H. Johnson, G. T. Westermark, and C. Betsholtz, “Islet amyloid polypeptide: pinpointing amino acid residues linked to amyloid fibril formation,” Proceedings of the National Academy of Sciences of the United States of America, vol. 87, no. 13, pp. 5036–5040, 1990. View at Publisher · View at Google Scholar
13. S. B. P. Chargé, E. J. P. de Koning, and A. Clark, “Effect of pH and insulin on fibrillogenesis of islet amyloid polypeptide in vitro,” Biochemistry, vol. 34, no. 44, pp. 14588–14593, 1995. View at Publisher · View at Google Scholar
14. A. Kapurniotu, J. Bernhagen, N. Greenfield, et al., “Contribution of advanced glycosylation to the amyloidogenicity of islet amyloid polypeptide,” European Journal of Biochemistry, vol. 251, no. 1-2, pp. 208–216, 1998. View at Publisher · View at Google Scholar
15. R. Kayed, J. Bernhagen, N. Greenfield, et al., “Conformational transitions of islet amyloid polypeptide (IAPP) in amyloid formation in vitro,” Journal of Molecular Biology, vol. 287, no. 4, pp. 781–796, 1999. View at Publisher · View at Google Scholar · View at PubMed
16. E. T. A. S. Jaikaran, C. E. Higham, L. C. Serpell, et al., “Identification of a novel human islet amyloid polypeptide $\beta$-sheet domain and factors influencing fibrillogenesis,” Journal of Molecular Biology, vol. 308, no. 3, pp. 515–525, 2001. View at Publisher · View at Google Scholar · View at PubMed
17. S. B. Padrick and A. D. Miranker, “Islet amyloid polypeptide: identification of long-range contacts and local order on the fibrillogenesis pathway,” Journal of Molecular Biology, vol. 308, no. 4, pp. 783–794, 2001. View at Publisher · View at Google Scholar · View at PubMed
18. S. B. Padrick and A. D. Miranker, “Islet amyloid: phase partitioning and secondary nucleation are central to the mechanism of fibrillogenesis,” Biochemistry, vol. 41, no. 14, pp. 4694–4703, 2002. View at Publisher · View at Google Scholar
19. J. L. Larson, E. Ko, and A. D. Miranker, “Direct measurement of islet amyloid polypeptide fibrillogenesis by mass spectrometry,” Protein Science, vol. 9, no. 2, pp. 427–431, 2000.
20. B. W. Koo and A. D. Miranker, “Contribution of the intrinsic disulfide to the assembly mechanism of islet amyloid,” Protein Science, vol. 14, no. 1, pp. 231–239, 2005. View at Publisher · View at Google Scholar · View at PubMed
21. J. A. Williamson and A. D. Miranker, “Direct detection of transient $\alpha$-helical states in islet amyloid polypeptide,” Protein Science, vol. 16, no. 1, pp. 110–117, 2007. View at Publisher · View at Google Scholar · View at PubMed
22. A. M. Ruschak and A. D. Miranker, “Fiber-dependent amyloid formation as catalysis of an existing reaction pathway,” Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 30, pp. 12341–12346, 2007. View at Publisher · View at Google Scholar · View at PubMed
23. J. D. Harper and P. T. Lansbury, Jr., “Models of amyloid seeding in Alzheimer's disease and scrapie: mechanistic truths and physiological consequences of the time-dependent solubility of amyloid proteins,” Annual Review of Biochemistry, vol. 66, pp. 385–407, 1997. View at Publisher · View at Google Scholar · View at PubMed
24. H. Naiki, K. Higuchi, M. Hosokawa, and T. Takeda, “Fluorometric determination of amyloid fibrils in vitro using the fluorescent dye, thioflavine T,” Analytical Biochemistry, vol. 177, no. 2, pp. 244–249, 1989. View at Publisher · View at Google Scholar
25. L. R. McLean and A. Balasubramaniam, “Promotion of $\beta$-structure by interaction of diabetes associated polypeptide (amylin) with phosphatidylcholine,” Biochimica et Biophysica Acta, vol. 1122, no. 3, pp. 317–320, 1992. View at Publisher · View at Google Scholar
26. C. Goldsbury, K. Goldie, J. Pellaud, et al., “Amyloid fibril formation from full-length and fragments of amylin,” Journal of Structural Biology, vol. 130, no. 2-3, pp. 352–362, 2000. View at Publisher · View at Google Scholar · View at PubMed
27. S. A. Jayasinghe and R. Langen, “Lipid membranes modulate the structure of islet amyloid polypeptide,” Biochemistry, vol. 44, no. 36, pp. 12113–12119, 2005. View at Publisher · View at Google Scholar · View at PubMed
28. J. D. Knight, J. A. Hebda, and A. D. Miranker, “Conserved and cooperative assembly of membrane-bound $\alpha$-helical states of islet amyloid polypeptide,” Biochemistry, vol. 45, no. 31, pp. 9496–9508, 2006. View at Publisher · View at Google Scholar · View at PubMed
29. M. Anguiano, R. J. Nowak, and P. T. Lansbury, Jr., “Protofibrillar islet amyloid polypeptide permeabilizes synthetic vesicles by a pore-like mechanism that may be relevant to type II diabetes,” Biochemistry, vol. 41, no. 38, pp. 11338–11343, 2002. View at Publisher · View at Google Scholar
30. J. D. Green, C. Goldsbury, J. Kistler, G. J. S. Cooper, and U. Aebi, “Human amylin oligomer growth and fibril elongation define two distinct phases in amyloid formation,” Journal of Biological Chemistry, vol. 279, no. 13, pp. 12206–12212, 2004. View at Publisher · View at Google Scholar · View at PubMed
31. R. Kayed, Y. Sokolov, B. Edmonds, et al., “Permeabilization of lipid bilayers is a common conformation-dependent activity of soluble amyloid oligomers in protein misfolding diseases,” Journal of Biological Chemistry, vol. 279, no. 45, pp. 46363–46366, 2004. View at Publisher · View at Google Scholar · View at PubMed
32. J.-C. Rochet, K. A. Conway, and P. T. Lansbury, Jr., “Inhibition of fibrillization and accumulation of prefibrillar oligomers in mixtures of human and mouse $\alpha$-synuclein,” Biochemistry, vol. 39, no. 35, pp. 10619–10626, 2000. View at Publisher · View at Google Scholar
33. C. G. Glabe and R. Kayed, “Common structure and toxic function of amyloid oligomers implies a common mechanism of pathogenesis,” Neurology, vol. 66, no. 2, supplement 1, pp. S74–S78, 2006. View at Publisher · View at Google Scholar · View at PubMed
34. R. Kayed, E. Head, J. L. Thompson, et al., “Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis,” Science, vol. 300, no. 5618, pp. 486–489, 2003. View at Publisher · View at Google Scholar · View at PubMed
35. C. Goldsbury, G. J. S. Cooper, K. N. Goldie, et al., “Polymorphic fibrillar assembly of human amylin,” Journal of Structural Biology, vol. 119, no. 1, pp. 17–27, 1997. View at Publisher · View at Google Scholar · View at PubMed
36. O. Sumner Makin and L. C. Serpell, “Structural characterisation of islet amyloid polypeptide fibrils,” Journal of Molecular Biology, vol. 335, no. 5, pp. 1279–1288, 2004. View at Publisher · View at Google Scholar
37. S. A. Jayasinghe and R. Langen, “Identifying structural features of fibrillar islet amyloid polypeptide using site-directed spin labeling,” Journal of Biological Chemistry, vol. 279, no. 46, pp. 48420–48425, 2004. View at Publisher · View at Google Scholar · View at PubMed
38. M. R. Sawaya, S. Sambashivan, R. Nelson, et al., “Atomic structures of amyloid cross-$\beta$ spines reveal varied steric zippers,” Nature, vol. 447, no. 7143, pp. 453–457, 2007. View at Publisher · View at Google Scholar · View at PubMed
39. D. F. Moriarty and D. P. Raleigh, “Effects of sequential proline substitutions on amyloid formation by human ${\text{amylin}}_{20-29}$,” Biochemistry, vol. 38, no. 6, pp. 1811–1818, 1999. View at Publisher · View at Google Scholar · View at PubMed
40. D. T. S. Rijkers, J. W. M. Höppener, G. Posthuma, C. J. M. Lips, and R. M. J. Liskamp, “Inhibition of amyloid fibril formation of human amylin by N-alkylated amino acid and $\alpha$-hydroxy acid residue containing peptides,” Chemistry: A European Journal, vol. 8, no. 18, pp. 4285–4291, 2002. View at Publisher · View at Google Scholar
41. Y. Porat, Y. Mazor, S. Efrat, and E. Gazit, “Inhibition of islet amyloid polypeptide fibril formation: a potential role for heteroaromatic interactions,” Biochemistry, vol. 43, no. 45, pp. 14454–14462, 2004. View at Publisher · View at Google Scholar · View at PubMed
42. L.-M. Yan, M. Tatarek-Nossol, A. Velkova, A. Kazantzis, and A. Kapurniotu, “Design of a mimic of nonamyloidogenic and bioactive human islet amyloid polypeptide (IAPP) as nanomolar affinity inhibitor of IAPP cytotoxic fibrillogenesis,” Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 7, pp. 2046–2051, 2006. View at Publisher · View at Google Scholar · View at PubMed
43. A. Abedini, F. Meng, and D. P. Raleigh, “A single-point mutation converts the highly amyloidogenic human islet amyloid polypeptide into a potent fibrillization inhibitor,” Journal of the American Chemical Society, vol. 129, no. 37, pp. 11300–11301, 2007. View at Publisher · View at Google Scholar · View at PubMed
44. R. Azriel and E. Gazit, “Analysis of the minimal amyloid-forming fragment of the islet amyloid polypeptide—an experimental support for the key role of the phenylalanine residue in amyloid formation,” Journal of Biological Chemistry, vol. 276, no. 36, pp. 34156–34161, 2001. View at Publisher · View at Google Scholar · View at PubMed
45. P. Marek, A. Abedini, B. Song, et al., “Aromatic interactions are not required for amyloid fibril formation by islet amyloid polypeptide but do influence the rate of fibril formation and fibril morphology,” Biochemistry, vol. 46, no. 11, pp. 3255–3261, 2007. View at Publisher · View at Google Scholar · View at PubMed
46. Y. Mazor, S. Gilead, I. Benhar, and E. Gazit, “Identification and characterization of a novel molecular-recognition and self-assembly domain within the islet amyloid polypeptide,” Journal of Molecular Biology, vol. 322, no. 5, pp. 1013–1024, 2002. View at Publisher · View at Google Scholar
47. L. A. Scrocchi, K. Ha, Y. Chen, L. Wu, F. Wang, and P. E. Fraser, “Identification of minimal peptide sequences in the (8–20) domain of human islet amyloid polypeptide involved in fibrillogenesis,” Journal of Structural Biology, vol. 141, no. 3, pp. 218–227, 2003. View at Publisher · View at Google Scholar
48. A. Abedini and D. P. Raleigh, “The role of His-18 in amyloid formation by human islet amyloid polypeptide,” Biochemistry, vol. 44, no. 49, pp. 16284–16291, 2005. View at Publisher · View at Google Scholar · View at PubMed
49. A. Clark and M. R. Nilsson, “Islet amyloid: a complication of islet dysfunction or an aetiological factor in type 2 diabetes?,” Diabetologia, vol. 47, no. 2, pp. 157–169, 2004. View at Publisher · View at Google Scholar · View at PubMed
50. J. D. Knight and A. D. Miranker, “Phospholipid catalysis of diabetic amyloid assembly,” Journal of Molecular Biology, vol. 341, no. 5, pp. 1175–1187, 2004. View at Publisher · View at Google Scholar · View at PubMed
51. E. Sparr, M. F. M. Engel, D. V. Sakharov, et al., “Islet amyloid polypeptide-induced membrane leakage involves uptake of lipids by forming amyloid fibers,” FEBS Letters, vol. 577, no. 1-2, pp. 117–120, 2004. View at Publisher · View at Google Scholar · View at PubMed
52. D. H. J. Lopes, A. Meister, A. Gohlke, A. Hauser, A. Blume, and R. Winter, “Mechanism of islet amyloid polypeptide fibrillation at lipid interfaces studied by infrared reflection absorption spectroscopy,” Biophysical Journal, vol. 93, no. 9, pp. 3132–3141, 2007. View at Publisher · View at Google Scholar · View at PubMed
53. A. Quist, I. Doudevski, H. Lin, et al., “Amyloid ion channels: a common structural link for protein-misfolding disease,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 30, pp. 10427–10432, 2005. View at Publisher · View at Google Scholar · View at PubMed
54. M. F. M. Engel, H. Yigittop, R. C. Elgersma, et al., “Islet amyloid polypeptide inserts into phospholipid monolayers as monomer,” Journal of Molecular Biology, vol. 356, no. 3, pp. 783–789, 2006. View at Publisher · View at Google Scholar · View at PubMed
55. N. Arispe, H. B. Pollard, and E. Rojas, “Giant multilevel cation channels formed by Alzheimer disease amyloid $\beta$-protein [A$\beta$P-(1–40)] in bilayer membranes,” Proceedings of the National Academy of Sciences of the United States of America, vol. 90, no. 22, pp. 10573–10577, 1993. View at Publisher · View at Google Scholar
56. N. Arispe, H. B. Pollard, and E. Rojas, “The ability of amyloid $\beta$-protein [A$\beta$P (1–40)] to form ${\text{Ca}}^{2+}$ channels provides a mechanism for neuronal death in Alzheimer's disease,” Annals of the New York Academy of Sciences, vol. 747, pp. 256–266, 1994.
57. T. A. Mirzabekov, M.-C. Lin, and B. L. Kagan, “Pore formation by the cytotoxic islet amyloid peptide amylin,” Journal of Biological Chemistry, vol. 271, no. 4, pp. 1988–1992, 1996. View at Publisher · View at Google Scholar
58. B. Konarkowska, J. F. Aitken, J. Kistler, S. Zhang, and G. J. S. Cooper, “The aggregation potential of human amylin determines its cytotoxicity towards islet $\beta$-cells,” FEBS Journal, vol. 273, no. 15, pp. 3614–3624, 2006. View at Publisher · View at Google Scholar · View at PubMed
59. A. Demuro, E. Mina, R. Kayed, S. C. Milton, I. Parker, and C. G. Glabe, “Calcium dysregulation and membrane disruption as a ubiquitous neurotoxic mechanism of soluble amyloid oligomers,” Journal of Biological Chemistry, vol. 280, no. 17, pp. 17294–17300, 2005. View at Publisher · View at Google Scholar · View at PubMed
60. Y. Porat, S. Kolusheva, R. Jelinek, and E. Gazit, “The human islet amyloid polypeptide forms transient membrane-active prefibrillar assemblies,” Biochemistry, vol. 42, no. 37, pp. 10971–10977, 2003. View at Publisher · View at Google Scholar · View at PubMed
61. K. Balali-Mood, R. H. Ashley, T. Hauß, and J. P. Bradshaw, “Neutron diffraction reveals sequence-specific membrane insertion of pre-fibrillar islet amyloid polypeptide and inhibition by rifampicin,” FEBS Letters, vol. 579, no. 5, pp. 1143–1148, 2005. View at Publisher · View at Google Scholar · View at PubMed
62. T. A. Harroun, J. P. Bradshaw, and R. H. Ashley, “Inhibitors can arrest the membrane activity of human islet amyloid polypeptide independently of amyloid formation,” FEBS Letters, vol. 507, no. 2, pp. 200–204, 2001. View at Publisher · View at Google Scholar
63. J. D. Green, L. Kreplak, C. Goldsbury, et al., “Atomic force microscopy reveals defects within mica supported lipid bilayers induced by the amyloidogenic human amylin peptide,” Journal of Molecular Biology, vol. 342, no. 3, pp. 877–887, 2004. View at Publisher · View at Google Scholar · View at PubMed
64. J. J. Meier, R. Kayed, C.-Y. Lin, et al., “Inhibition of human IAPP fibril formation does not prevent $\beta$-cell death: evidence for distinct actions of oligomers and fibrils of human IAPP,” American Journal of Physiology, vol. 291, no. 6, pp. E1317–E1324, 2006. View at Publisher · View at Google Scholar · View at PubMed
65. M. Bucciantini, E. Giannoni, F. Chiti, et al., “Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases,” Nature, vol. 416, no. 6880, pp. 507–511, 2002. View at Publisher · View at Google Scholar · View at PubMed
66. J. I. Kourie, A. L. Culverson, P. V. Farrelly, C. L. Henry, and K. N. Laohachai, “Heterogeneous amyloid-formed ion channels as a common cytotoxic mechanism: implications for therapeutic strategies against amyloidosis,” Cell Biochemistry and Biophysics, vol. 36, no. 2-3, pp. 191–207, 2002. View at Publisher · View at Google Scholar · View at PubMed
67. J. R. Brender, U. H. N. Dürr, D. Heyl, M. B. Budarapu, and A. Ramamoorthy, “Membrane fragmentation by an amyloidogenic fragment of human islet amyloid polypeptide detected by solid-state NMR spectroscopy of membrane nanotubes,” Biochimica et Biophysica Acta, vol. 1768, no. 9, pp. 2026–2029, 2007. View at Publisher · View at Google Scholar · View at PubMed
68. C.-J. Huang, C.-Y. Lin, L. Haataja, et al., “High expression rates of human islet amyloid polypeptide induce endoplasmic reticulum stress-mediated $\beta$-cell apoptosis, a characteristic of humans with type 2 but not type 1 diabetes,” Diabetes, vol. 56, no. 8, pp. 2016–2027, 2007. View at Publisher · View at Google Scholar · View at PubMed
69. C.-Y. Lin, T. Gurlo, R. Kayed, et al., “Toxic human islet amyloid polypeptide (h-IAPP) oligomers are intracellular, and vaccination to induce anti-toxic oligomer antibodies does not prevent h-IAPP-induced $\beta$-cell apoptosis in h-IAPP transgenic mice,” Diabetes, vol. 56, no. 5, pp. 1324–1332, 2007. View at Publisher · View at Google Scholar · View at PubMed
70. S. Andrikopoulos, C. B. Verchere, J. C. Teague, et al., “Two novel immortal pancreatic $\beta$-cell lines expressing and secreting human islet amyloid polypeptide do not spontaneously develop islet amyloid,” Diabetes, vol. 48, no. 10, pp. 1962–1970, 1999. View at Publisher · View at Google Scholar
71. M. F. M. Engel, L. Khémtemourian, C. Kleijer, et al., “Membrane damage by human islet amyloid polypeptide through fibril growth at the membrane,” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 16, pp. 6033–6038, 2008.
72. M. Wogulis, S. Wright, D. Cunningham, T. Chilcote, K. Powell, and R. E. Rydel, “Nucleation-dependent polymerization is an essential component of amyloid-mediated neuronal cell death,” Journal of Neuroscience, vol. 25, no. 5, pp. 1071–1080, 2005. View at Publisher · View at Google Scholar · View at PubMed
73. H. Zhao, A. Jutila, T. Nurminen, S. A. Wickström, J. Keski-Oja, and P. K. J. Kinnunen, “Binding of endostatin to phosphatidylserine-containing membranes and formation of amyloid-like fibers,” Biochemistry, vol. 44, no. 8, pp. 2857–2863, 2005. View at Publisher · View at Google Scholar · View at PubMed
74. H. Zhao, E. K. J. Tuominen, and P. K. J. Kinnunen, “Formation of amyloid fibers triggered by phosphatidylserine-containing membranes,” Biochemistry, vol. 43, no. 32, pp. 10302–10307, 2004. View at Publisher · View at Google Scholar · View at PubMed
75. G. P. Gellermann, T. R. Appel, A. Tannert, et al., “Raft lipids as common components of human extracellular amyloid fibrils,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 18, pp. 6297–6302, 2005. View at Publisher · View at Google Scholar · View at PubMed
76. S. Gilead, H. Wolfenson, and E. Gazit, “Molecular mapping of the recognition interface between the islet amyloid polypeptide and insulin,” Angewandte Chemie International Edition, vol. 45, no. 39, pp. 6476–6480, 2006. View at Publisher · View at Google Scholar · View at PubMed
77. P. Westermark, Z.-C. Li, G. T. Westermark, A. Leckström, and D. F. Steiner, “Effects of $\beta$ cell granule components on human islet amyloid polypeptide fibril formation,” FEBS Letters, vol. 379, no. 3, pp. 203–206, 1996. View at Publisher · View at Google Scholar
78. E. T. A. S. Jaikaran, M. R. Nilsson, and A. Clark, “Pancreatic $\beta$-cell granule peptides form heteromolecular complexes which inhibit islet amyloid polypeptide fibril formation,” Biochemical Journal, vol. 377, part 3, pp. 709–716, 2004. View at Publisher · View at Google Scholar · View at PubMed
79. I. Rustenbeck, A. Matthies, and S. Lenzen, “Lipid composition of glucose-stimulated pancreatic islets and insulin-secreting tumor cells,” Lipids, vol. 29, no. 10, pp. 685–692, 1994. View at Publisher · View at Google Scholar
80. T. Konno, S. Oiki, and T. Morii, “Synergistic action of polyanionic and non-polar cofactors in fibrillation of human islet amyloid polypeptide,” FEBS Letters, vol. 581, no. 8, pp. 1635–1638, 2007. View at Publisher · View at Google Scholar · View at PubMed